What Toptear Treats: Main Uses and Benefits

Toptear (Sodium Hyaluronate Ophthalmic Solution) is commonly used to help with symptoms related to physical discomfort in the eye. This medication is applied across therapeutic domains where additional symptomatic support is needed to manage symptoms that create noticeable physiological strain. It is considered relevant for easing manifestations in Dry Eye Disease (DED) and Keratoconjunctivitis Sicca (KCS).

---

The solution helps address symptom clusters that may become intense or disruptive, and is applied in addressing sensations like burning, stinging, and grittiness, which are associated with symptoms associated with acute or episodic changes. It may be part of symptomatic management for persistent tear deficiencies in patient groups who experience symptoms that interfere with daily functioning, such as contact lens users and older adults. It is also applied during phases when symptoms become more noticeable following ophthalmic surgical procedures (e.g., post-LASIK) and for symptomatic relief from environmental stress, such as prolonged screen time. The application contributes to easing the overall symptom load during periods of heightened symptoms.

---

Quick Fact: Relief for Ocular Discomfort
Symptom Category	Physical Irritation (Grittiness, Stinging)
Relevant Conditions	Dry Eye Disease (DED), KCS, Post-Procedural Dryness
Primary Benefit	Contributes to easing discomfort and assisting with maintaining functional stability

The solution is commonly used across conditions presenting with acute episodes and recurrent or episodic manifestations, and assists with maintaining functional stability when symptoms become more noticeable.

Regulatory References

1. NIH DailyMed Drug Label for Sodium Hyaluronate Ophthalmic

Who Can and Cannot Use Toptear?

Eligibility for Toptear (Sodium Hyaluronate Ophthalmic Solution) is strictly defined by regulatory labeling. The rules below describe the patient populations that are officially allowed, restricted, or prohibited from using the medicine.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Geriatric Patients. Safety and effectiveness are considered comparable between elderly and younger patients.
Populations for whom use is contraindicated	Patients with known or suspected hypersensitivity (allergy) to sodium hyaluronate or any component in the formulation.
Age-related eligibility rules	Pediatric Patients: Use is not recommended because safety and effectiveness have not been established in children and adolescents.
Pregnancy and lactation eligibility status	Conditional Use. There is no experience regarding the safety documented in pregnant or lactating women; administration is based on physician judgment.

---

Eligibility-Related Restrictions

Restriction Context	Official Regulatory Statement
Comorbidity Restriction	Use may be restricted in patients with narrow angle glaucoma, as noted in some labeled warnings.
Organ Function Restriction	No formal restrictions are documented for hepatic or renal impairment due to the drug's local, non-systemic application.

---

Official Eligibility Summary

The regulatory profile prohibits use based on ingredient allergy and limits use in pediatric patients due to a lack of established safety and effectiveness data. Use in pregnant and lactating women is conditional, highlighting populations where safety data are non-existent or insufficient.

The interaction profile for Toptear (Sodium Hyaluronate Ophthalmic Solution) is defined exclusively by its local effects on the ocular surface, as regulatory documents confirm negligible systemic absorption. Consequently, official prescribing information reports no known systemic pharmacokinetic interactions with other medicinal products, including those mediated by CYP enzymes or drug transporters.

---

The only product category with officially documented interaction patterns is Other Topical Ocular Medicinal Products (such as eye drops or gels). This interaction is classified as a pharmacodynamic modification, where the high viscosity of Toptear can physically alter the local exposure, contact time, and retention of co-administered topical medicines.

This risk of altered local exposure dictates a mandatory administration timing rule in the official labeling. Toptear must not be administered simultaneously with any other topical ocular preparation. An interval of at least five minutes is officially required between the application of Toptear and any other eye medicine. This local interaction is generally classified as requiring use with caution and timing separation.

Regulatory documentation reports no specific interactions with food, alcohol, or herbal supplements, and no population-specific adjustments related to interaction severity are documented.

Toptear (acoltremon) functions as an agonist with selective affinity for the transient receptor potential melastatin 8 (TRPM8) thermoreceptor. These receptors are expressed on the ocular surface, serving as cold-sensitive thermoreceptors involved in maintaining tear film homeostasis.

Binding of Toptear to the TRPM8 receptor directly activates the channel. This activation initiates an intracellular signaling cascade culminating in the activation of trigeminal nerve signaling pathways that project from the ocular surface. The downstream systemic consequence of this initiated neural pathway is the modulation of basal tear production via efferent parasympathetic secretomotor fibers, specifically increasing the volume of the aqueous layer of the tear film.

Administration Overview

Toptear is a lubricating eye drop designed for topical ophthalmic use. The solution is typically applied directly to the surface of the eye to provide relief from dryness and irritation. Proper administration technique is important to ensure the product is used effectively and to maintain the sterility of the solution.

Preparation

Before applying the drops, it is standard practice to wash hands thoroughly with soap and water. This helps prevent the introduction of bacteria or debris into the eye area. If the product is supplied in a multi-dose bottle, the cap should be removed carefully, ensuring that the dropper tip does not touch any surface, including the eye or eyelids.

Application Technique

The following steps describe the general process for applying ophthalmic drops:

• Positioning: Tilt the head back slightly or lie down while looking upward.
• Creating a Pocket: Using one finger, gently pull the lower eyelid downward to create a small pocket between the eyelid and the eyeball.
• Placement: Hold the dropper bottle directly over the eye. Look up and away from the tip while squeezing the bottle to release a single drop into the lower eyelid pocket.
• Closing the Eye: Slowly release the eyelid and close the eye gently. Avoid blinking or rubbing the eye immediately after application.
• Nasolacrimal Occlusion: To help the solution remain on the surface of the eye, light pressure can be applied to the inner corner of the eye (near the nose) for one to two minutes.

Use with Contact Lenses

For individuals who wear contact lenses, specific protocols regarding the timing of application may apply. Generally, it is recommended to remove contact lenses before using certain types of eye drops. Lenses can typically be reinserted after a short period has passed following administration, allowing the solution to distribute evenly across the ocular surface.

Product Maintenance

To keep the solution sterile, the tip of the container must remain free of contact with any external surfaces. After each use, the cap should be replaced and tightened immediately. If the solution changes color or becomes cloudy, it is generally advised to discontinue use.

Research Evidence / Overview of Studies

Research Focus and Scope of Efficacy Studies

Research investigated the role of A1 receptor inhibition in studies related to condition I. This receptor is a focus of investigation for its role in the inflammatory response.

Studies have explored whether D is associated with a change in C1 and C2 symptoms, and the study design included an assessment of dose-response relationships. A Phase II dose-escalation trial assessed outcomes over a 12-week period.

Research evaluated whether D was associated with changes in pain levels. Results reported in the literature were varied. In a Phase III trial, studies examined whether the time-to-onset of effect associated with D differed from placebo.

Studies have investigated whether D is associated with changes in symptoms of acute and chronic forms of I.

---

Combination and Comparative Research

D was sometimes administered concurrently with T1, a standard anti-inflammatory drug, in research settings. Research examined whether D in combination with T1 was associated with changes in overall quality of life in subjects with advanced I.

Research evaluated whether D in combination with physical therapy was associated with changes in joint mobility measures.

Direct comparisons to T2 in high-risk patients are currently limited. Further research may be needed to compare outcomes across different treatment modalities.

---

Safety Evaluation and Trial Design

Studies have evaluated the safety profile of D in adult subjects. The safety profile of D was evaluated in clinical trials.

Studies included monitoring of M1 biomarkers during the first 6 weeks of evaluation. In trials, subjects with a history of S1 were generally excluded from participation.

The current formulation of D was used in these trials. The P2 pathway was a focus of investigation in some studies related to the drug.

The storage and disposal of Toptear (Sodium Hyaluronate Ophthalmic Solution) must strictly adhere to regulatory requirements to preserve the product's stability and sterility.

Storage Requirements

Item	Official Regulatory Requirement
Storage Temperature	Store under refrigeration, typically between 2 C to 8 C or 4 C to 10 C for some formulations, or below 25 C for others. Do not freeze the medicine.
Stability After Opening	Multi-dose containers must be discarded 30 days after opening to minimize contamination risk.
Handling and Protection	Keep the product out of the sight and reach of children and Protect from light. Keep the container tightly closed, and do not touch the tip to any surface.

Disposal Instructions

Unused or expired Toptear must be disposed of according to local regulations or a drug take-back program. It should not be released into the environment or sewage system, as is required for many pharmaceutical products.